Andrew Sharabi

Title(s)Assistant Professor Of Clinical, Radiation Medicine and Applied Science
SchoolHealth Sciences
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Johns Hopkins HospitalResidency2015Radiation Oncology
    Baylor College of MedicineM.D.2010Medicine
    Baylor College of MedicinePh.D.2009Immunology
    University of California at San DiegoB.S.2001Bioengineering
    Collapse Awards and Honors
    University of California at San Diego2017UCSD ACTRI KL2 Translational Science Award
    Johns Hopkins University2015Roentgen Resident/Fellow Research Award
    Johns Hopkins University2015American Society for Radiation Oncology (ASTRO) Travel Award
    Johns Hopkins University2014American Society for Radiation Oncology (ASTRO) Resident Clinical Basic Science Research Award
    Johns Hopkins University2013ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant
    Johns Hopkins University2012John G. Rangos Medal of Honor for Creativity in Cancer Discovery
    Baylor College of Medicine20081st Place Talk, MD/PhD Program Annual Symposium
    Baylor College of Medicine20071st Place Talk, Immunology Department Annual Symposium
    Baylor College of Medicine20072nd Place Poster, Center for Cell and Gene Therapy Conference
    Baylor College of Medicine20062nd Place Poster, Immunology Department Annual Symposium
    Baylor College of Medicine20062nd Place Talk, Center for Cell and Gene Therapy Conference
    Baylor College of Medicine2003BCM M.D./Ph.D. Program Academic Achievement Award
    University of California at San Diego2001Bioengineering Department Highest Academic Achievement Award
    University of California at San Diego2001Summa Cum Laude
    University of California at San Diego2000Phi Beta Kappa National Honor Society
    University of California at San Diego 1997  - 2001Provost's Honors

    Collapse Overview 
    Collapse Overview
    Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He sees patients at the La Jolla Moores Cancer Center and his specialties include Prostate (Genitourinary) and Head and Neck Cancers, as well as Skin Cancer and Thoracic Malignancies. He treats patients with novel radiotherapy techniques including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and 4-D computed tomography, and Stereotactic Body Radiation Therapy (SBRT). Dr. Sharabi is a member and serves on the Education Committee of American Society of Therapeutic Radiology and Oncology (ASTRO) as well as National Cancer Institute (NCI) Clinical Trials Planning Committee Panels.

    Dr. Sharabi is a recognized expert on the effects of radiation on the immune system and the ability of radiation therapy to synergize with checkpoint blockade immunotherapy. He is the PI of multiple investigator initiated clinical trials combining radiation therapy with anti-PD-1 immunotherapy and has published his work in top journals including Cancer Discovery and Lancet Oncology. His laboratory in the Moores Cancer Center focuses on development of novel immunotherapies and strategies to combine radiation with immunotherapy.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491. PMID: 30936880.
      View in: PubMed
    2. Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res. 2019 Jul 15; 25(14):4211-4223. PMID: 30814108.
      View in: PubMed
    3. Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB. Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. Front Oncol. 2018; 8:435. PMID: 30386736.
      View in: PubMed
    4. Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy. Clin Cancer Res. 2018 Oct 15; 24(20):5058-5071. PMID: 29898992.
      View in: PubMed
    5. Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW, Pardoll DM, Drake CG. TNFa and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Cancer Immunol Res. 2018 04; 6(4):422-433. PMID: 29472271.
      View in: PubMed
    6. Bryant AK, Huynh-Le MP, Simpson DR, Gupta S, Sharabi AB, Murphy JD. Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. JAMA Oncol. 2018 Jan 01; 4(1):120-122. PMID: 28975226.
      View in: PubMed
    7. Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, Daly ME, Murphy JD. Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans. Ann Thorac Surg. 2018 Feb; 105(2):425-431. PMID: 29198624.
      View in: PubMed
    8. Bryant AK, Mudgway R, Huynh-Le MP, Simpson DR, Mell LK, Gupta S, Sharabi AB, Murphy JD. Effect of CD4 Count on Treatment Toxicity and Tumor Recurrence in Human Immunodeficiency Virus-Positive Patients With Anal Cancer. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):478-485. PMID: 29102276.
      View in: PubMed
    9. Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P. Immunotherapy and radiation in glioblastoma. J Neurooncol. 2017 Sep; 134(3):531-539. PMID: 28567588.
      View in: PubMed
    10. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. PMID: 28550027.
      View in: PubMed
    11. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. PMID: 28351930.
      View in: PubMed
    12. Green G, Carmona R, Zakeri K, Lee CH, Borgan S, Marhoon Z, Sharabi A, Mell LK. Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review. PLoS One. 2016; 11(7):e0156489. PMID: 27383192; PMCID: PMC4934683.
    13. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138.
      View in: PubMed
    14. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015 Oct; 16(13):e498-509. PMID: 26433823.
      View in: PubMed
    15. Robertson SP, Quon H, Kiess AP, Moore JA, Yang W, Cheng Z, Afonso S, Allen M, Richardson M, Choflet A, Sharabi A, McNutt TR. A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patients. Med Phys. 2015 Jul; 42(7):4329-37. PMID: 26133630.
      View in: PubMed
    16. Sharabi AB, Tran PT, Lim M, Drake CG, Deweese TL. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park). 2015 May; 29(5):331-40. PMID: 25979541; PMCID: PMC4814161.
    17. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015 Apr; 3(4):345-55. PMID: 25527358; PMCID: PMC4390444.
    18. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014; 2:14. PMID: 24883190; PMCID: PMC4039332.
    19. Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi AB, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol. 2013 Dec; 4(4):343-51. PMID: 24294505; PMCID: PMC3819776.
    20. Pinkawa M, Schoth F, Böhmer D, Hatiboglu G, Sharabi A, Song D, Eble MJ. Current standards and future directions for prostate cancer radiation therapy. Expert Rev Anticancer Ther. 2013 Jan; 13(1):75-88. PMID: 23259429.
      View in: PubMed
    21. Sharabi AB, Lee SH, Goodell MA, Huang XF, Chen SY. Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Cloning Stem Cells. 2009 Dec; 11(4):523-33. PMID: 20025523; PMCID: PMC2883497.
    22. Lee SH, Hong B, Sharabi A, Huang XF, Chen SY. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells. 2009 Jul; 27(7):1604-15. PMID: 19544467; PMCID: PMC4157827.
    23. Sharabi AB, Aldrich M, Sosic D, Olson EN, Friedman AD, Lee SH, Chen SY. Twist-2 controls myeloid lineage development and function. PLoS Biol. 2008 Dec 16; 6(12):e316. PMID: 19090621.
      View in: PubMed
    24. Koshikawa N, Minegishi T, Sharabi A, Quaranta V, Seiki M. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem. 2005 Jan 07; 280(1):88-93. PMID: 15525652.
      View in: PubMed
    25. Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, Malli R, Sharabi A, Hiden U, Graier W, Knöfler M, Andreae F, Wagner O, Quaranta V, Desoye G. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci. 2004 Mar 15; 117(Pt 8):1319-28. PMID: 15020672.
      View in: PubMed
    26. Koshikawa N, Schenk S, Moeckel G, Sharabi A, Miyazaki K, Gardner H, Zent R, Quaranta V. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. FASEB J. 2004 Feb; 18(2):364-6. PMID: 14688206.
      View in: PubMed
    27. Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, Maisi P. Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun. 2003 Apr 18; 303(4):1012-7. PMID: 12684035.
      View in: PubMed
    28. Hintermann E, Haake SK, Christen U, Sharabi A, Quaranta V. Discrete proteolysis of focal contact and adherens junction components in Porphyromonas gingivalis-infected oral keratinocytes: a strategy for cell adhesion and migration disabling. Infect Immun. 2002 Oct; 70(10):5846-56. PMID: 12228316.
      View in: PubMed
    29. Hintermann E, Bilban M, Sharabi A, Quaranta V. Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin. J Cell Biol. 2001 04 30; 153(3):465-78. PMID: 11331299.
      View in: PubMed